A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

Leanza, Gabriele Maria; Rando, Emanuele; Frondizi, Federico; Taddei, Eleonora; Giovannenze, Francesca; Horcajada Gallego, Juan Pablo; Scoppettuolo, Giancarlo; Torti, Carlo

doi:http://dx.doi.org/10.1007/s15010-024-02393-9

A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

License

Citation

Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP, Scoppettuolo G, Torti C. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025 Feb;53(1):15-23. DOI: 10.1007/s15010-024-02393-9

Abstract

Introduction: Dalbavancin is an antibiotic characterized by an extended half-life and efficacy against methicillin-resistant Staphylococci. Currently, there are only narrative reviews summarizing the evidence about the use of dalbavancin for infective endocarditis (IE), many of which are focused primarily on its use as consolidation therapy. For this reason, we conducted a systematic review to describe the clinical efficacy and the safety of dalbavancin in IE treatment. Methods: We searched for available evidence using the MEDLINE (PubMed), Embase, Scopus, Cochrane Library and Web of Science libraries, with no restrictions regarding the publication year. The risk of bias was performed using the Cochrane ROBINS-I tool for the comparative studies and the Newcastle-Ottawa Scale for descriptive studies. Results: Nine studies were included. All of them were observational. Native valve endocarditis was the most common kind of IE found in the studies¿ populations (128/263, 48.7%), followed by prosthetic valve endocarditis, and cardiovascular implantable electronic device-related endocarditis. Coagulase-negative Staphylococci were the most common pathogens isolated (83/269, 30.1%), followed by S. aureus, Enterococci spp and Streptococci spp. Five out of nine studies documented a clinical failure rate of less than 10%. Dalbavancin showed a favourable safety profile. Dalbavancin appears to be a promising option for the consolidation therapy of IE. However, further studies comparing dalbavancin with standard of care are needed. PROSPERO registration number: CRD42023430032.